<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00592072</url>
  </required_header>
  <id_info>
    <org_study_id>DK66108b_0505000079</org_study_id>
    <secondary_id>R37DK020495</secondary_id>
    <secondary_id>DK20495</secondary_id>
    <nct_id>NCT00592072</nct_id>
  </id_info>
  <brief_title>Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes</brief_title>
  <official_title>Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, there are no therapeutic agents that can minimize severe hypoglycemia (low blood
      sugar) and its effects on long-term brain function. The aim of this study is to determine
      whether the human brain is able to use medium chain fatty acids (MCFA) and/or their
      metabolites as an alternative fuel source during acute hypoglycemia in patients with Type 1
      Diabetes Mellitus (T1DM). The hypothesis is that medium chain fatty acids will provide a
      rapidly absorbed, non-carbohydrate fuel that will improve cognitive performance during
      episodes of hypoglycemia (low blood sugar.)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twelve subjects between the ages of 18 years and 55 years who have had Type 1 Diabetes
      Mellitus for more than five years and have had tight control of their diabetes as determined
      by screening blood work will be invited to participate. Each study subject will undergo two
      hypoglycemic clamp studies (a procedure where the blood sugar is closely regulated with
      intravenous insulin and glucose.) In these hypoglycemic clamp studies, cognitive testing will
      be performed during 90 minutes of normal blood glucose followed by 90 minutes of
      hypoglycemia. During the hypoglycemic period, either the MCFA or a placebo will be
      administered. Each subject will experience both conditions. The order in which the MCFA is
      given will be randomized.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immediate Verbal Memory</measure>
    <time_frame>90 minutes</time_frame>
    <description>Results of cognitive function in diabetic patients using tests such as digit symbol substitution (a test of memory), tests of everyday attention, telephone book searching and map searching during either administration of medium chain triglyceride oil or a control solution. The goal was to determine whether the human brain is able to use medium-chain fatty acids (MCFA) and /or their metabolites as an alternative fuel source and thus improve brain function during acute hypoglycemia in patients with type 1 diabetes. The lowest score is 0 and the highest score is 25. A higher score is an improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delayed Verbal Memory</measure>
    <time_frame>90 minutes</time_frame>
    <description>The highest score is 25 and the lowest score is 0. The higher scored indicate an improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Verbal Memory Recognition</measure>
    <time_frame>90 minutes</time_frame>
    <description>The highest score is 15. The lowest score is 0. Higher scores indicate an improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Digit Span Backward</measure>
    <time_frame>90 minutes</time_frame>
    <description>The highest score is 35. The lowest score is 0. The higher the score indicates an improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Letter/Number Sequencing</measure>
    <time_frame>90 minutes</time_frame>
    <description>The highest score is 21. The lowest score is 0. Higher scores indicate an improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Digit Symbol Coding</measure>
    <time_frame>90 minutes</time_frame>
    <description>The highest score is 133. The lowest score is 0. Higher scores indicate an improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Map Search (2min)</measure>
    <time_frame>90 minutes</time_frame>
    <description>The highest score is 80. The lowest score is 0. Higher scores indicate an improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Map Search (1min)</measure>
    <time_frame>90 minutes</time_frame>
    <description>The highest score is 80. The lowest score is 0. Higher scores indicate an improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Telephone Search</measure>
    <time_frame>90 minutes</time_frame>
    <description>This is a ratio of how many symbols are found during a certain period of time. The highest ratio is the best result.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Medium chain fatty acid (Octanoic and Decanoic acid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Splenda (Placebo Control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Medium chain fatty acid (Octanoic and Decanoic acid)</intervention_name>
    <description>Octanoic acid(67%) and Decanoic acid (27%); MCFA 50g total at 25 minute intervals with front loading of 20g then 10g for three administrations.</description>
    <arm_group_label>Medium chain fatty acid (Octanoic and Decanoic acid)</arm_group_label>
    <other_name>Medium Chain Triglycerides</other_name>
    <other_name>Octanoic and Decanoic acid</other_name>
    <other_name>Fractionated coconut oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Splenda (Placebo Control)</intervention_name>
    <description>Placebo drink will consist of dietary sweetener Splenda mixed in water at a concentration of 1g/100mL. An unsweetened cherry flavor Koolaid mix will be added at a concentration of 0.3g/100mL of the Splenda drink to enhance flavor.</description>
    <arm_group_label>Splenda (Placebo Control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 Diabetes Mellitus for greater than 5 years (C-peptide negative)

          -  Age 18-55 years

          -  Subject is on intensive insulin therapy resulting in a Hemoglobin A1c of less than
             7.5%

          -  History of frequent hypoglycemic events as defined as having at least one blood
             glucose of less than 60 mg/dl in the last four weeks

        Exclusion Criteria:

          -  History of hypoglycemia induced seizures

          -  Pregnancy

          -  Significant baseline anemia (hemoglobin &lt; 11.0g/dl or hematocrit &lt; 33%)

          -  A history of liver cirrhosis or porto-caval shunt surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Sherwin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <results_first_submitted>February 4, 2013</results_first_submitted>
  <results_first_submitted_qc>December 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 5, 2015</results_first_posted>
  <last_update_submitted>January 8, 2015</last_update_submitted>
  <last_update_submitted_qc>January 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>Medium Chain Fatty Acid</keyword>
  <keyword>Hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decanoic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MCT Intervention First, Then Placebo</title>
          <description>A total of 40 grams of medium-chain triglycerides (derived from coconut oil containing 67% octanoate, 27% decanaote, and 6% other fatty acids) is ingested at 25-min intervals with front loading of 20 grams then 10 grams twice</description>
        </group>
        <group group_id="P2">
          <title>Placebo Intervention First, Then MCT Intervention</title>
          <description>A total of 40 grams of cherry-flavored water sweetened with sucralose is ingested at 25-min intervals with front loading of 20 grams then 10 grams twice</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Sequence</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash Out Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Sequence</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline number of subjects reflects the number of subjects with baseline data</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Number of Subjects</title>
          <description>12 subjects started the study and 10 completed the study, however 11 subjects are reported in the baseline characteristics because one subjects withdrew before baseline data was collected.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.8" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immediate Verbal Memory</title>
        <description>Results of cognitive function in diabetic patients using tests such as digit symbol substitution (a test of memory), tests of everyday attention, telephone book searching and map searching during either administration of medium chain triglyceride oil or a control solution. The goal was to determine whether the human brain is able to use medium-chain fatty acids (MCFA) and /or their metabolites as an alternative fuel source and thus improve brain function during acute hypoglycemia in patients with type 1 diabetes. The lowest score is 0 and the highest score is 25. A higher score is an improvement.</description>
        <time_frame>90 minutes</time_frame>
        <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 1 Diabetes With MCT Oil</title>
            <description>Subjects ingested a drink containing MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
          <group group_id="O2">
            <title>Type 1 Diabetes Without MCT Oil</title>
            <description>Subjects ingested a drink without MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
        </group_list>
        <measure>
          <title>Immediate Verbal Memory</title>
          <description>Results of cognitive function in diabetic patients using tests such as digit symbol substitution (a test of memory), tests of everyday attention, telephone book searching and map searching during either administration of medium chain triglyceride oil or a control solution. The goal was to determine whether the human brain is able to use medium-chain fatty acids (MCFA) and /or their metabolites as an alternative fuel source and thus improve brain function during acute hypoglycemia in patients with type 1 diabetes. The lowest score is 0 and the highest score is 25. A higher score is an improvement.</description>
          <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Euglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.85" spread="0.66"/>
                    <measurement group_id="O2" value="17.36" spread="13.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.97" spread="1.13"/>
                    <measurement group_id="O2" value="13.28" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Delayed Verbal Memory</title>
        <description>The highest score is 25 and the lowest score is 0. The higher scored indicate an improvement.</description>
        <time_frame>90 minutes</time_frame>
        <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 1 Diabetes With MCT Oil</title>
            <description>Subjects ingested a drink containing MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
          <group group_id="O2">
            <title>Type 1 Diabetes Without MCT Oil</title>
            <description>Subjects ingested a drink without MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
        </group_list>
        <measure>
          <title>Delayed Verbal Memory</title>
          <description>The highest score is 25 and the lowest score is 0. The higher scored indicate an improvement.</description>
          <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Euglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.82" spread="1.25"/>
                    <measurement group_id="O2" value="15.33" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.80" spread="1.31"/>
                    <measurement group_id="O2" value="11.58" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Verbal Memory Recognition</title>
        <description>The highest score is 15. The lowest score is 0. Higher scores indicate an improvement.</description>
        <time_frame>90 minutes</time_frame>
        <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 1 Diabetes With MCT Oil</title>
            <description>Subjects ingested a drink containing MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
          <group group_id="O2">
            <title>Type 1 Diabetes Without MCT Oil</title>
            <description>Subjects ingested a drink without MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
        </group_list>
        <measure>
          <title>Verbal Memory Recognition</title>
          <description>The highest score is 15. The lowest score is 0. Higher scores indicate an improvement.</description>
          <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Euglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.19" spread="0.53"/>
                    <measurement group_id="O2" value="14.27" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.29" spread="0.50"/>
                    <measurement group_id="O2" value="12.14" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Digit Span Backward</title>
        <description>The highest score is 35. The lowest score is 0. The higher the score indicates an improvement.</description>
        <time_frame>90 minutes</time_frame>
        <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 1 Diabetes With MCT Oil</title>
            <description>Subjects ingested a drink containing MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
          <group group_id="O2">
            <title>Type 1 Diabetes Without MCT Oil</title>
            <description>Subjects ingested a drink without MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
        </group_list>
        <measure>
          <title>Digit Span Backward</title>
          <description>The highest score is 35. The lowest score is 0. The higher the score indicates an improvement.</description>
          <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Euglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.05"/>
                    <measurement group_id="O2" value="0.64" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.05"/>
                    <measurement group_id="O2" value="0.54" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Letter/Number Sequencing</title>
        <description>The highest score is 21. The lowest score is 0. Higher scores indicate an improvement.</description>
        <time_frame>90 minutes</time_frame>
        <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 1 Diabetes With MCT Oil</title>
            <description>Subjects ingested a drink containing MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
          <group group_id="O2">
            <title>Type 1 Diabetes Without MCT Oil</title>
            <description>Subjects ingested a drink without MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
        </group_list>
        <measure>
          <title>Letter/Number Sequencing</title>
          <description>The highest score is 21. The lowest score is 0. Higher scores indicate an improvement.</description>
          <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Euglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.04" spread="0.81"/>
                    <measurement group_id="O2" value="11.07" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.97" spread="0.76"/>
                    <measurement group_id="O2" value="9.92" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Digit Symbol Coding</title>
        <description>The highest score is 133. The lowest score is 0. Higher scores indicate an improvement.</description>
        <time_frame>90 minutes</time_frame>
        <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 1 Diabetes With MCT Oil</title>
            <description>Subjects ingested a drink containing MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
          <group group_id="O2">
            <title>Type 1 Diabetes Without MCT Oil</title>
            <description>Subjects ingested a drink without MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
        </group_list>
        <measure>
          <title>Digit Symbol Coding</title>
          <description>The highest score is 133. The lowest score is 0. Higher scores indicate an improvement.</description>
          <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Euglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.50" spread="5.27"/>
                    <measurement group_id="O2" value="74.04" spread="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.99" spread="4.56"/>
                    <measurement group_id="O2" value="68.56" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Map Search (2min)</title>
        <description>The highest score is 80. The lowest score is 0. Higher scores indicate an improvement.</description>
        <time_frame>90 minutes</time_frame>
        <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 1 Diabetes With MCT Oil</title>
            <description>Subjects ingested a drink containing MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
          <group group_id="O2">
            <title>Type 1 Diabetes Without MCT Oil</title>
            <description>Subjects ingested a drink without MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
        </group_list>
        <measure>
          <title>Map Search (2min)</title>
          <description>The highest score is 80. The lowest score is 0. Higher scores indicate an improvement.</description>
          <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Euglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.30" spread="1.70"/>
                    <measurement group_id="O2" value="75.04" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.11" spread="1.51"/>
                    <measurement group_id="O2" value="74.67" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Map Search (1min)</title>
        <description>The highest score is 80. The lowest score is 0. Higher scores indicate an improvement.</description>
        <time_frame>90 minutes</time_frame>
        <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 1 Diabetes With MCT Oil</title>
            <description>Subjects ingested a drink containing MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
          <group group_id="O2">
            <title>Type 1 Diabetes Without MCT Oil</title>
            <description>Subjects ingested a drink without MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
        </group_list>
        <measure>
          <title>Map Search (1min)</title>
          <description>The highest score is 80. The lowest score is 0. Higher scores indicate an improvement.</description>
          <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Euglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.11" spread="4.16"/>
                    <measurement group_id="O2" value="50.35" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.42" spread="3.19"/>
                    <measurement group_id="O2" value="42.94" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Telephone Search</title>
        <description>This is a ratio of how many symbols are found during a certain period of time. The highest ratio is the best result.</description>
        <time_frame>90 minutes</time_frame>
        <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 1 Diabetes With MCT Oil</title>
            <description>Subjects ingested a drink containing MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
          <group group_id="O2">
            <title>Type 1 Diabetes Without MCT Oil</title>
            <description>Subjects ingested a drink without MCT oil prior to euglycemic-hypoglycemic clamp.</description>
          </group>
        </group_list>
        <measure>
          <title>Telephone Search</title>
          <description>This is a ratio of how many symbols are found during a certain period of time. The highest ratio is the best result.</description>
          <population>With the validation span test, a decrease in cognitive performance from euglycemia to hypoglycemia (22+/-2.3 vs 13.4+/-2.5) or a difference of 8.6 has been reported. Using this, a sample size of 12 will provide 80% power to detect a 23% (i.e. 2 unit) attenuation of the effect of hypoglycemia on cognitive performance.</population>
          <units>symbols/ 90 min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Euglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread="0.17"/>
                    <measurement group_id="O2" value="3.14" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="0.20"/>
                    <measurement group_id="O2" value="3.46" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MCT Intervention</title>
        </group>
        <group group_id="E2">
          <title>Placebo Intervention</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No technical limitations were seen.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Robert Sherwin</name_or_title>
      <organization>Yale School of Medicine</organization>
      <phone>203-785-6222</phone>
      <email>robert.sherwin@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

